Other disorders, such as cerebral palsy, start with a discrete lesion early in development and express varied developmental phenotypes, with neuroplasticity occurring in response to use-driven rewiring of circuits (79–81) or the introduction of neuroprotective agents (e.g., erythropoietin, caffeine) (82–84). The gene discussed is EPO; the disease is cerebral palsy.